Inmed Pharmaceuticals Stock Performance
| INM Stock | USD 0.93 0.17 22.37% |
The company retains a Market Volatility (i.e., Beta) of 1.6, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, InMed Pharmaceuticals will likely underperform. At this point, InMed Pharmaceuticals has a negative expected return of -0.55%. Please make sure to check out InMed Pharmaceuticals' potential upside, as well as the relationship between the rate of daily change and relative strength index , to decide if InMed Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days InMed Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2026. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Last Split Factor 1:20 | Dividend Date 2020-07-06 | Last Split Date 2024-11-14 |
1 | InMed Provides Update on BayMedica Commercial Business | 12/12/2025 |
2 | InMed Announces Results of 2025 Annual General and Special Meeting - Investing News Network | 12/17/2025 |
3 | Will InMed Pharmaceuticals Inc. stock beat revenue estimates - 2025 Year in Review Growth Focused Entry Reports - ulpravda.ru | 01/08/2026 |
4 | Aug Summary Will InMed Pharmaceuticals Inc. stock go up in YEAR - July 2025 Selloffs Weekly Chart Analysis and Guides - mfd.ru | 01/28/2026 |
5 | InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update | 02/11/2026 |
InMed Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 143.00 in InMed Pharmaceuticals on December 5, 2025 and sell it today you would lose (50.00) from holding InMed Pharmaceuticals or give up 34.97% of portfolio value over 90 days. InMed Pharmaceuticals is generating negative expected returns assuming volatility of 5.7595% on return distribution over 90 days investment horizon. In other words, 51% of stocks are less volatile than InMed, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
InMed Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of InMed Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.93 | 90 days | 0.93 | about 85.52 |
Based on a normal probability distribution, the odds of InMed Pharmaceuticals to move above the current price in 90 days from now is about 85.52 (This InMed Pharmaceuticals probability density function shows the probability of InMed Stock to fall within a particular range of prices over 90 days) .
InMed Pharmaceuticals Price Density |
| Price |
Predictive Modules for InMed Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as InMed Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.InMed Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. InMed Pharmaceuticals is not an exception. The market had few large corrections towards the InMed Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold InMed Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of InMed Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.44 | |
β | Beta against Dow Jones | 1.60 | |
σ | Overall volatility | 0.17 | |
Ir | Information ratio | -0.07 |
InMed Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of InMed Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for InMed Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| InMed Pharmaceuticals generated a negative expected return over the last 90 days | |
| InMed Pharmaceuticals has high historical volatility and very poor performance | |
| InMed Pharmaceuticals has some characteristics of a very speculative penny stock | |
| InMed Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 4.94 M. Reported Net Loss for the year was (8.16 M) with profit before taxes, overhead, and interest of 1.34 M. | |
| InMed Pharmaceuticals has about 9.35 M in cash with (7.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.98, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| InMed Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from aol.com: Video Florida man slams Jaguar into school bus, arrested for battery hours later Deputies |
InMed Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of InMed Stock often depends not only on the future outlook of the current and potential InMed Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. InMed Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 976 K | |
| Cash And Short Term Investments | 15.1 M |
InMed Pharmaceuticals Fundamentals Growth
InMed Stock prices reflect investors' perceptions of the future prospects and financial health of InMed Pharmaceuticals, and InMed Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on InMed Stock performance.
| Return On Equity | -0.97 | ||||
| Return On Asset | -0.5 | ||||
| Profit Margin | (1.70) % | ||||
| Operating Margin | (2.59) % | ||||
| Current Valuation | (6.27 M) | ||||
| Shares Outstanding | 2.92 M | ||||
| Price To Book | 0.21 X | ||||
| Price To Sales | 0.49 X | ||||
| Revenue | 4.94 M | ||||
| Gross Profit | 1.34 M | ||||
| EBITDA | (7.26 M) | ||||
| Net Income | (8.16 M) | ||||
| Cash And Equivalents | 9.35 M | ||||
| Cash Per Share | 9.98 X | ||||
| Total Debt | 1.01 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 3.52 X | ||||
| Book Value Per Share | 3.42 X | ||||
| Cash Flow From Operations | (7.77 M) | ||||
| Earnings Per Share | (6.09) X | ||||
| Market Capitalization | 2.22 M | ||||
| Total Asset | 21.23 M | ||||
| Retained Earnings | (159.73 M) | ||||
| Working Capital | 11.03 M | ||||
About InMed Pharmaceuticals Performance
By examining InMed Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into InMed Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that InMed Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 3.33 | 3.17 | |
| Return On Tangible Assets | (4.61) | (4.84) | |
| Return On Capital Employed | 5.93 | 6.23 | |
| Return On Assets | (2.78) | (2.92) | |
| Return On Equity | 6.45 | 6.78 |
Things to note about InMed Pharmaceuticals performance evaluation
Checking the ongoing alerts about InMed Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for InMed Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| InMed Pharmaceuticals generated a negative expected return over the last 90 days | |
| InMed Pharmaceuticals has high historical volatility and very poor performance | |
| InMed Pharmaceuticals has some characteristics of a very speculative penny stock | |
| InMed Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 4.94 M. Reported Net Loss for the year was (8.16 M) with profit before taxes, overhead, and interest of 1.34 M. | |
| InMed Pharmaceuticals has about 9.35 M in cash with (7.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.98, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| InMed Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from aol.com: Video Florida man slams Jaguar into school bus, arrested for battery hours later Deputies |
- Analyzing InMed Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether InMed Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining InMed Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating InMed Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of InMed Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of InMed Pharmaceuticals' stock. These opinions can provide insight into InMed Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Will Biotechnology sector continue expanding? Could InMed diversify its offerings? Factors like these will boost the valuation of InMed Pharmaceuticals. Market participants price InMed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every InMed Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (6.09) | Revenue Per Share | Quarterly Revenue Growth (0.26) | Return On Assets | Return On Equity |
Understanding InMed Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects InMed's accounting equity. The concept of intrinsic value - what InMed Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push InMed Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, InMed Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.